Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Immune-related adverse events
•
Neurology
•
Neuromuscular
How do you manage immunotherapy-induced myasthenia gravis?
Answer from: at Academic Institution
My go-to algorithm is well-represented in the paper by Dr. @Adeel Zubair et al. Zubair et al., PMID 36439604
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
NCCN "Management of Immunotherapy-Related Toxicities" has a useful 'cheat sheet' as a quick reference for the overnight call.
Sign in or Register to read more
19074
19390
Related Questions
How does one interpret an SPEP showing potentially obscured but non-quantifiable M-spike however an IFE showing monoclonal protein?
How do you manage follow up for patient who was diagnosed with pineal gland germinomas with drop metastatic to the spinal cord?
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
Do you always biopsy patients who present with classic skin findings of dermatomyositis?
How do you treat nocturnal leg cramps?
How do you counsel patients with dermatomyositis on sun protection?
In what circumstances would you consider use of IDH inhibitors in high-grade astrocytomas?
Should IVIG dosing in patients with autoimmune disease (i.e., dermatomyositis) who become pregnant continue to be based on actual weight at the time of each infusion, or should it be limited to pre-pregnancy weight?
How do you time CSF analysis for suspected CNS lymphoma in patients who are on steroids?
Do you find IVIG to be an effective maintenance therapy for myasthenia gravis?